Helix BioPharma Corp. (HBP : TSX)
Common Stock
$1.45
CAD
+0.00 (%)
Last updated: 2026-09-21
Get HBP alerts:
HBP
Helix BioPharma Corp.
WealthAwesomePerformance
1 Day
+0.00%
1 Week
+3.57%
1 Month
-26.40%
YTD
-39.58%
Key Statistics
Market Cap
$110.75M
52W High
$5.40
52W Low
$1.10
P/E Ratio
-
50 Day MA
$1.64
200 Day MA
$1.82
Beta
-0.27
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/21/2026 | $1.50 | $1.50 | $1.45 | $1.45 | $1.45 | 602 |
| 9/18/2026 | $1.45 | $1.45 | $1.45 | $1.45 | $1.45 | 100 |
| 9/17/2026 | $1.54 | $1.54 | $1.40 | $1.40 | $1.40 | 452 |
| 9/16/2026 | $1.40 | $1.40 | $1.40 | $1.40 | $1.40 | 112 |
| 9/15/2026 | $1.40 | $1.53 | $1.38 | $1.38 | $1.38 | 7,248 |
| 9/14/2026 | $1.43 | $1.43 | $1.40 | $1.40 | $1.40 | 1,105 |
| 9/11/2026 | $1.56 | $1.56 | $1.43 | $1.45 | $1.45 | 3,836 |
| 9/10/2026 | $1.60 | $1.60 | $1.49 | $1.52 | $1.52 | 6,201 |
| 9/9/2026 | $1.75 | $1.75 | $1.58 | $1.63 | $1.63 | 5,473 |
| 9/8/2026 | $1.80 | $1.81 | $1.64 | $1.80 | $1.80 | 3,308 |
Analyst Price Targets
Based on analyst covering HBP · as of Sep 17, 2026
Wall Street analysts forecast HBP stock price to rise 72.4% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+72.4% Upside
Current Price
C$1.45
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
77.8%
Annualized
90-Day Vol
56.9%
Annualized
Trend (90d)
+36.3%
Annualized drift
90d Mean
C$1.65
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.51 | C$1.16 – C$1.98 |
| 60 trading days | C$1.58 | C$1.08 – C$2.31 |
| 90 trading days | C$1.65 | C$1.04 – C$2.63 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Helix BioPharma Corp.
Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer; and LDOS007, which is in phase Ib/II for the treatment of lung cancer. It develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company has an agreement with metaShape Pharma AG for covering LEUMUNA, within the field of adipose tissue-related and metabolic diseases. Helix BioPharma Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-3.25M
- Profit Margin
- 0.00%
- ROE (TTM)
- -49.99%
- EPS (Diluted)
- -0.04
- Book Value
- 0.19
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
🔄 Recent Splits
1-for-5
Aug 16, 2024
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About HBP
Market movers
Recent TSX movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| SLT-U | Saltire Capital Ltd. | $2.28 | +30.29% |
| SLT | Saltire Capital Ltd. | $3.15 | +29.63% |
| VGZ | Vista Gold Corporation | $3.86 | +20.63% |
| MSV | Minco Silver Corporation | $0.54 | +14.89% |
| RTG | RTG Mining Inc | $0.04 | +12.50% |
| MOLY | Greenland Resources Inc. | $1.82 | +10.30% |
| CHLT | Custom Health Holdings Inc. | $8.23 | +9.59% |
| LAM | Laramide Resources Ltd. | $0.58 | +9.43% |
HBP.TO news timeline
15 articles covering HBP.TO, most recent first
LatestWhy Helix BioPharma Corp. stock fell yesterday
September 2026
- What's Going On With Helix BioPharma Corp. Stock Monday?
- Why Helix BioPharma Corp. stock plummeted yesterday
- Why Helix BioPharma Corp. stock plummeted yesterday
- Why Helix BioPharma Corp. stock is plummeting today
- Why Helix BioPharma Corp. stock plummeted yesterday
- What's Going On With Helix BioPharma Corp. Stock Thursday?
- Why Helix BioPharma Corp. stock surged yesterday
- Why Helix BioPharma Corp. stock plummeted yesterday
August 2026
- What's Going On With Helix BioPharma Corp. Stock Thursday?
- What's Going On With Helix BioPharma Corp. Stock Thursday?
- Why Helix BioPharma Corp. stock is gaining today
- Why Helix BioPharma Corp. stock is rising today
- Why Helix BioPharma Corp. stock is skyrocketing today
- What's Going On With Helix BioPharma Corp. Stock Thursday?